Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 5, 2016

PathMaker begins first human clinical trial of MyoRegulator to treat spasticity

US-based clinical-stage neurotechnology company PathMaker Neurosystems has commenced the first human clinical trial in collaboration with Northwell Health and the Feinstein Institute for Medical Research to assess the safety and efficacy of MyoRegulator to treat spasticity.

US-based clinical-stage neurotechnology company PathMaker Neurosystems has commenced the first human clinical trial in collaboration with Northwell Health and the Feinstein Institute for Medical Research to assess the safety and efficacy of MyoRegulator to treat spasticity.

Spasticity is a common occurrence in many patients who have suffered from a stroke or who have cerebral palsy, multiple sclerosis, spinal cord injury, brain injury and other neurological conditions.

The disabling condition is characterised by tight or stiff muscles and an inability to control those muscles.

"It is my hope that at the conclusion of this trial, we will see that MyoRegulator is a safe and effective treatment option."

More than 15 million patients worldwide say they are being affected by spasticity.

Feinstein Institute Laboratory of Biomedical Science investigator and lead investigator of the study Bruce Volpe said: "I see patients who can no longer open doors or feed themselves as a result of suffering from spasticity.

"It is my hope that at the conclusion of this trial, we will see that MyoRegulator is a safe and effective treatment option."

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

Approved by Institutional Review Board (IRB), the MyoRegulator clinical trials have also been confirmed as a non-significant risk (NSR) device study by the US Food and Drug Administration (FDA).

An NSR designation allows the pursuit of a clinical trial without an approval of Investigational Device Exemption (IDE).

MyoRegulator is a non-invasive device used to treat spasticity afflicted patients leveraging on Pathmaker’s proprietary DoubleStim technology for multi-site neurostimulation.

Patients with spasticity have damaged neural pathways that create hyperexcitable spinal circuits and can be addressed by the DoubleStim technology which has been shown in published animal studies to be able to suppress the hyperexcitability, thereby leading to reduced muscle spasticity.

However, MyoRegulator is an investigational device and is limited by the US law for investigational use only.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU